Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.

Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.